Andres Cruz-Herranz

Dr. Cruz-Herranz is the Director of Clinical Development at Prilenia. In his role, he is responsible for designing Clinical Development plans, as well as clinical trial protocols with a patient-centric focus. In addition, he provides oversight of clinical studies and contributes to regulatory and clinical publication activities.

Dr. Cruz-Herranz brings more than 10 years of experience working across clinical, research, and drug development roles. Most recently, he served as Associate Medical Director at Denali Therapeutics, where he was responsible for the Early Clinical Development of candidate disease-modifying therapies for ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases. Prior to this, he was a Clinical Research Fellow at Genentech-Roche, where he was involved in Phase 3 and 4 global clinical trials in Multiple Sclerosis and Alzheimer´s diseases.

Prior to his career in industry, Dr. Cruz-Herranz obtained an M.D. at the Autonomous University of Madrid and a Ph.D. at the University of Barcelona. He completed a residency in clinical neurology at La Paz University Hospital in Madrid, and a postdoc at the University of California San Francisco, where his research focused on in vivo retinal imaging to develop translational biomarkers for disease progression and therapeutic response in demyelinating diseases such as Multiple Sclerosis.